Literature DB >> 6459374

Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF.

A D Hess, P J Tutschka, G W Santos.   

Abstract

The mechanism whereby Cyclosporin A (CsA) inhibits secondary mixed lymphocyte responses was assessed. CsA added to secondary MLR cultures inhibited proliferation and induction of cytolytic lymphocyte activity. This inhibition was found to be associated with the inhibition of T lymphocyte stimulating growth factor(s) (TCGF) production in the supernatants of secondary MLR cultures. As little as 1.0 micrograms/ml of CsA added to secondary MLR cultures resulted in no measurable TCGF activity. In contrast, moderate doses of CsA (1.0, 2.5 micrograms/ml), which completely inhibited the secondary MLR response to alloantigen, did not inhibit the proliferative and CML response of alloantigen-primed lymphocytes to these stimulating growth factors. Even at high doses of CsA (20 micrograms/ml), substantial levels of proliferation (50% of control response) and CML induction (60% of control response) were observed when the primed cells were exposed to secondary MLR supernatants containing TCGF activity. It was concluded that inhibition of secondary mixed lymphocyte responses by CsA may be due in part to the inhibition of TCGF production rather than the inhibition of the effect of TCGF on mature cytotoxic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6459374

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

Review 1.  Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity.

Authors:  P A Keown
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

2.  Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives.

Authors:  M Schleuning; V Brumme; W Wilmanns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

Review 3.  A practical guide to the management of distal ulcerative colitis.

Authors:  S Ardizzone; G Bianchi Porro
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

4.  Cyclosporin A has differential effects on the responses of murine B cells to TI antigens and B-cell mitogens.

Authors:  A D Higham; R A Sells; S Marshall-Clarke
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

5.  Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A.

Authors:  A Meyrier; P Simon; G Perret; M C Condamin-Meyrier
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-22

Review 6.  The influence of cyclosporin A on cell-mediated immunity.

Authors:  A W Thomson; L M Webster
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

7.  Natural killer-cell activity, interferon-alpha 2 production, and interleukin-2 production in cyclosporine-treated and conventionally immunosuppressed human allograft recipients.

Authors:  P J Guillou; G R Giles; C W Ramsden
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

8.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

Review 9.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.

Authors:  W J Sandborn; R H Wiesner; W J Tremaine; N F Larusso
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.